Wyeth

Enzon Pharmaceuticals, Inc.

Santaris Pharma A/s

Dana-Farber-Cancer Institute Inc.

Yixian Zhang

Kimberly A Gillis

Zhengxing Qu

Lee Greenberger

James Elliott Bradner

Fuk-Wah Sum

Adam Matthew Gilbert

Lijing Chen

Philip Frost

Lee Dalton Jennings

Dennis William Powell

Jesper Worm

Scott Lee Kincaid

Matthew Gregory Bursavich

Christopher J Ott

Rajanikanth Bandaru

Yongbo Hu

Tammy M Sadler

Lee Martin Greenberger

Tammy Michelle Sadler

The disclosure relates to oligonucleotide compounds (oligomers) that target Myc mRNA in a cell, leading to reduced expression of Myc. Reduction of Myc expression is beneficial for the treatment of certain disorders, such as hyperproliferative disorders (e.g., cancer). The disclosure provides therapeutic compositions comprising oligomers and methods for modulating the expression of Myc using said oligomers, including methods of treatment.

LNA antisense oligonucleotides for the modulation of Myc expression

The present invention relates to oligomer compounds (oligomers) for the treatment and prevention of acute myeloid leukemia, which target GLI2 mRNA in a cell, leading to reduced expression of GLI2.

RNA antagonists targeting GLI2 for the treatment of leukemia

The invention provides the combination use of antisense oligomers targeting androgen receptor mRNA and androgen receptor binding inhibitors that reduce androgen receptor activity for the treatment of androgen receptor related medical disorders, such as cancers, particularly prostate cancers and breast cancers.

Methods for treating androgen receptor dependent disorders including cancers

The present invention relates to compounds of formula I: wherein R, R, R, R, R, and Rare defined herein.

Anilino-pyrimidine analogs

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating prostate cancer. FKBP markers are provided, wherein changes in the levels of expression of one or more of the FKBP markers is correlated with the presence of prostate cancer.

Expression analysis of FKBP54 in assessing prostate cancer therapy

The invention relates to methods for detecting, characterizing, preventing, and treating prostate cancer. KIAA markers are provided, wherein changes in the levels of expression of one or more of the KIAA markers is correlated with the presence of prostate cancer.

Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer

Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer

This invention provides a method of treating or inhibiting an estrogen receptor positive carcinoma in a mammal in need thereof, which comprises providing said mammal with an effective amount of a combination of a rapamycin and an antiestrogen.

Method of treating estrogen receptor positive carcinoma

Growing community of inventors

Pearl River, NY, United States of America

Yixian Zhang